$DGX

Davis J. E. sold $2.4M of DGX

Davis J. E. (CEO and President) sold 10,000 shares of QUEST DIAGNOSTICS INC (DGX) at $242.72 ($2.43M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davis J. E.
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Bearish
medium confidence
Mentioned
$DGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXBearishMed
01

Why it matters

The disclosed sale adds a modest negative data point to DGX's recent positive momentum.

02

Market read

Insider sale is a primary disclosure that may influence short‑term trading sentiment for DGX.

03

What to watch

Recent earnings beat and strong cash flow may offset concerns from the insider sale.

Relevance 5/10Novelty 7/10Timing: post‑market filing on Sep 3, 2026

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$DGXBearishMedium confidence
Context

CEO Davis J. E. sold 10,000 shares for $2.4 M via a 10b5‑1 plan, reducing his stake to 122,423 shares.

Expected impact

Potential short‑term pressure on DGX, likely limited to a few percent.

Evidence & confidence

Form 4 is primary disclosure; the $2.4 M sale is material enough to affect sentiment but not large enough to drive a major move.

Market effects

May prompt analysts to review insider sentiment across health‑care services.

Limited to U.S. markets; no broader regional effect.

Low global relevance; only impacts investors tracking Quest Diagnostics.

Counterpoint

The sale could be a routine liquidity event under a pre‑arranged plan, not a bearish signal.

Key entities

  • Quest Diagnostics Inc.

    Provider of diagnostic testing services, ticker DGX.

  • Davis J. E.

    CEO and President of Quest Diagnostics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

$LLYHighAI 9/10

FDA Clears New Alzheimer’s Blood Test for People 55 and Older - WOWO News/Talk 92.3 FM and 1190 AM

The FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.

$DGXHighAI 8/10

Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?

Quest Diagnostics (DGX) hit a 52-week high, driven by consistent earnings beats. It reported EPS of $3.12 vs. $2.81 estimate, with revenue beating consensus by 2.15%. The company has a Zacks Rank of #2 (Buy) and a VGM Score of B. DGX trades at 21.6X current fiscal year EPS estimates. Option Care Health (OPCH), a peer, also shows strong fundamentals and a Zacks Rank of #2.

$DGXMedAI 8/10

Why Quest Diagnostics Stock Climbed This Past Week

Quest Diagnostics (NYSE: DGX) shares rose over 8% last week after the company raised its full-year outlook. In Q2, revenue increased 10% to $3 billion, with adjusted EPS up 19% to $3.12. Quest projects full-year revenue around $12 billion and adjusted EPS of $11.05 to $11.25, citing growth and margin gains from automation and AI.